extracorporeal

Home>Tag:extracorporeal
Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By |2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples.  Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Oct 18 2022

Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes

By |2022-10-17T20:12:29-04:00October 18th, 2022|Investor News, Medical, News, Press Releases|1 Comment

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases Jackson Center, PA, October 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has successfully eliminated various antibiotic resistant bacteria from buffer solution , in-vitro, through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria.  The combined ...

Oct 12 2022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

By |2022-10-11T20:09:20-04:00October 12th, 2022|Investor News, News, Press Releases, Uncategorized|0 Comments

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, PA, October 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies.  Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd’s ...

Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By |2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|1 Comment

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”.  The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By |2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing.  PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By |2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

Jun 8 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

By |2022-06-07T21:21:57-04:00June 8th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes.  Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...

Feb 8 2022

Halberd Eliminates 100% of Tau Protein From CSF – The 9th of 10 Target Neurodegenerative Disease Antigens

By |2022-02-07T18:58:11-05:00February 8th, 2022|Featured, Investor News, News|0 Comments

Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases. Jackson Center, PA, February 8, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process.  Excess Tau in CSF ...

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By |2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Go to Top